ACET has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACET has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Adicet Bio has the Financial Strength Rank of 7.
Good Sign:
Adicet Bio Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.GuruFocus does not calculate Adicet Bio's interest coverage with the available data. As of today, Adicet Bio's Altman Z-Score is 0.00.
For the Biotechnology subindustry, Adicet Bio's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Adicet Bio's Financial Strength distribution charts can be found below:
* The bar in red indicates where Adicet Bio's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Adicet Bio's Interest Expense for the months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the months ended in Dec. 2023 was $-31.57 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $17.70 Mil.
Adicet Bio's Interest Coverage for the quarter that ended in Dec. 2023 is
GuruFocus does not calculate Adicet Bio's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Adicet Bio's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
Debt to Revenue Ratio | = | Total Debt (Q: Dec. 2023 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (3.221 | + | 17.703) | / | 0 | |
= | N/A |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Adicet Bio has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicet Bio (NAS:ACET) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Adicet Bio has the Financial Strength Rank of 7.
Thank you for viewing the detailed overview of Adicet Bio's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Chen Schor | director, officer: See Remarks | PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Katie Peng | director | C/O ADICET BIO, INC., 200 BERKELEY STREET, 19TH FLOOR, BOSTON MA 02116 |
Steve Dubin | director | |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Carl L Gordon | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Don Healey | officer: Chief Technology Officer | 2635 TECHNOLOGY FOREST BOULEVARD, THE WOODLANDS TX 77381 |
Blake Aftab | officer: Chief Scientific Officer | C/O ADICET BIO, INC., 200 CLARENDON STREET, FLOOR 6, BOSTON MA 02116 |
Francesco Galimi | officer: Chief Medical Officer | 12930 VIA ESPERIA, DEL MAR CA 92014 |
Aya Jakobovits | director | 3135 HUTTON DRIVE, BEVERLY HILLS CA 90210 |
Orbimed Genesis Gp Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Andrew Sinclair | director | C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065 |
Michael Kauffman | director | C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459 |
Bastiano Sanna | director | C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON MA 02210 |
Orbimed Capital Gp V Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Carrie Krehlik | officer: Chief Human Resources Officer | 6015 COLTON BLVD, OAKLAND CA 94611 |
From GuruFocus
By Business Wire • 01-23-2024
By Business Wire Business Wire • 05-18-2023
By Business Wire • 10-31-2023
By Business Wire • 01-03-2024
By Business Wire • 08-02-2023
By Business Wire • 12-29-2023
By Business Wire Business Wire • 05-09-2023
By Business Wire • 08-31-2023
By Business Wire Business Wire • 02-01-2023
By Business Wire Business Wire • 05-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.